DDInter262 DDInter1016
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Epoprostenol
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen